Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

9-nitrocamptothecin-cyclodextrin inclusion compound and preparation method thereof as well as pharmaceutical composition containing cyclodextrin inclusion compound

A technology of cyclodextrin inclusion compound and nitrocamptothecin, which can be used in drug combinations, medical preparations containing active ingredients, antineoplastic drugs, etc., and can solve problems such as low bioavailability and poor solubility of 9-NC , to achieve the effect of improving dissolution rate, solubility and stability

Inactive Publication Date: 2014-03-05
NANJING UNIVERSITY OF TRADITIONAL CHINESE MEDICINE
View PDF3 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] Aiming at the technical problems of poor solubility and low bioavailability of 9-NC that cannot be solved in the existing preparation technology, the present invention provides 9-nitrocamptothecin-cyclodextrin package, the purpose of which is to improve the water solubility of 9-NC, It can be developed into a liquid preparation to meet different clinical needs; at the same time, it can also improve the in vivo absorption of 9-NC solid preparation and increase its bioavailability

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • 9-nitrocamptothecin-cyclodextrin inclusion compound and preparation method thereof as well as pharmaceutical composition containing cyclodextrin inclusion compound
  • 9-nitrocamptothecin-cyclodextrin inclusion compound and preparation method thereof as well as pharmaceutical composition containing cyclodextrin inclusion compound
  • 9-nitrocamptothecin-cyclodextrin inclusion compound and preparation method thereof as well as pharmaceutical composition containing cyclodextrin inclusion compound

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 19-N

[0032] Phase solubility curve experiment of embodiment 19-NC and hydroxypropyl-β-cyclodextrin (HP-β-CD)

[0033] Different amounts of HP-β-CD were dissolved in 3mL PBS (pH 5.0), prepared into a series of HP-β-CD solutions with a concentration, placed in stoppered test tubes, and excess 9-NC was added to each tube, respectively at 25 ℃, 37℃, 60℃ constant temperature water bath shake for 48h, take the suspension, centrifuge at 12000rpm for 10min, take the supernatant, measure the absorbance value, and calculate the concentration. Taking the concentration of 9-NC (mmol / L) as the ordinate and the concentration of HP-β-CD (mmol / L) as the abscissa, draw the equilibrium phase solubility curves at 25°C, 37°C, and 60°C, and the results are shown in the table 1.

[0034] Table 1 Phase solubility curves at different temperatures

[0035] Table l Phase solubility curve under different temperature

[0036]

[0037] It can be seen from Table 1 that the phase solubility curves are all ...

Embodiment 2

[0038] Example 2 Primary screening of 9-NC: HP-β-CD molecular molar ratio: preparation of 9-nitrocamptothecin-cyclodextrin package, the steps are as follows:

[0039] 1) 9-NC was made into 10ml of saturated acetone solution, and 13 parts were prepared, that is, 14.9mg of 9-NC in each part was dissolved in 10ml of acetone solution, and the amount of 9-NC was 0.03788mmol;

[0040] 2) According to the 9-NC:HP-β-CD molecular molar ratio of 1:30, 50, 60, 80, 100, 110, 120, 130, 140, 150, 160, 180, 200, weigh the cyclodextrin amount, and were dissolved in 5ml of water to make a cyclodextrin solution;

[0041] 3) Slowly add 13 parts of 9-NC saturated acetone solution dropwise to 13 parts of cyclodextrin solutions with different cyclodextrin concentrations, and magnetically stir at 60°C until the acetone is completely volatilized to obtain a suspension;

[0042]4) Centrifuge the prepared suspension at 2000 r.p.m for 10 min, take the supernatant and freeze-dry to obtain 9-NC-cyclodext...

Embodiment 3

[0048] Embodiment 3 Orthogonal experiments optimize the best preparation process parameters

[0049] By the result obtained in Example 2, further use the orthogonal experiment design to optimize the wrapping process, for influencing factors: the wrapping ratio (A) of medicine and HP-β-CD, the wrapping time (B) and the effect of HP-β-CD The aqueous solution concentration (C) was investigated. Take L9 (3 4 ) Orthogonal table arrangement experiment, and the packaging process optimization was carried out with the drug content of 9-NC in the finished package as the investigation index. See Table 2 for the level table of each factor, and Table 3 for the results.

[0050] Table 2 Factors and levels of orthogonal experiment

[0051] Table2Factors and levels of orthogonal test

[0052]

[0053] Table 3 Orthogonal test results

[0054] Table3 The programs and results of orthogonal test

[0055]

[0056] Orthogonal test results show that the best wrapping process is A 1 B 2...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a 9-nitrocamptothecin (NC)-cyclodextrin inclusion compound aiming at the technical problems of poor solubility and low bioavailability of 9-nitrocamptothecin in the prior art. The 9-NC-cyclodextrin inclusion compound comprises an active ingredient 9-NC of which the molecular mole ratio is 1:(30-200), an inclusion agent beta-CD or a derivant thereof. A concrete preparation method comprises the following steps: dropwise adding a 9-NC-acetone saturated solution to a CD solution; magnetically stirring at 25-60 DEG C until acetone completely volatilizes; taking supernate to carry out freeze drying after centrifuging the obtained suspension, so as to obtain 9-NC-CD inclusion compound powder. Meanwhile, the invention provides a pharmaceutical composition containing the 9-NC-CD inclusion compound and a pharmaceutically acceptable excipient. Compared with a 9-NC free drug, the solubility of the inclusion compound provided by the invention is increased by over 300 times; meanwhile, the inclusion compound displays higher lactone stability and in-vitro slow-release effect. An X-ray diffraction analysis method and a thermal analysis method indicate that 9-NC in the inclusion compound is completely included, and the reliability of the technology is further verified. Therefore, the inclusion compound can be developed into a liquid preparation, also can improve in vivo absorption of a 9-NC solid preparation, and the bioavailability is improved.

Description

technical field [0001] The invention belongs to the field of western medicines, and specifically relates to a 9-nitrocamptothecin-cyclodextrin package, a preparation method thereof, and a pharmaceutical composition containing the package. Background technique [0002] 9-nitrocamptothecin (9-NC), also known as rubitecan, is a new type of camptothecin derivative developed by Supergen Corporation of the United States. The drug is an ideal antitumor drug. Camptothecin drugs have a balance between the two forms of lactone and carboxylate in both humans and animals (such as figure 1 ), while the lactone type is recognized as the main active form with antitumor effects, and the carboxylate type is the ineffective form [1] . [0003] However, the poor solubility, instability and low bioavailability of 9-NC limit the development of its liquid preparations such as injections, and are also the main reasons for hindering its effect; Degrades rapidly in the blood. In order to improv...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K47/48A61K31/4745A61P35/00
Inventor 顾薇陈军杨希雄陆姗姗严旭
Owner NANJING UNIVERSITY OF TRADITIONAL CHINESE MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com